{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:ruclosporin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ruclosporin is a calcineurin inhibitor that was developed as an immunosuppressant. Information about the further development of this compound is not available.
Status:
Investigational
Source:
INN:coblopasvir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:alteminostat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00876421: Phase 2 Interventional Completed Overactive Bladder
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:orforglipron [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:tigulixostat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01449630: Phase 1 Interventional Completed Healthy Volunteers
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01435044: Phase 2 Interventional Completed Hepatitis C, Chronic
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
PSI-352938 is a nucleoside derivative patented by Pharmasset, Inc. as an antiviral agent. PSI-352938 acts as a novel cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine-5'-monophosphate with potent anti-HCV activity. PSI-352938 inhibits HCV genotype (GT) 1b replicon replication with 50% effective concentrations (EC50s) of 0.13 ± 0.076 μM, and active against GT 1a and 2a replicons and infectious viruses PSI-352938 retained full activity against replicons containing the S282T substitution, which confers resistance to certain 2'-substituted nucleoside/nucleotide analogs. In April 2013, because of hepatic toxicity, Gilead Sciences discontinued the development of PSI-352938.
Status:
Investigational
Source:
NCT03792672: Phase 1 Interventional Completed Healthy Volunteers
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
